3 Stocks Moving The Drugs Industry Upward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 12 points (0.1%) at 14,943 as of Thursday, Sept. 5, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,432 issues advancing vs. 1,453 declining with 120 unchanged.

The Drugs industry currently sits up 0.7% versus the S&P 500, which is up 0.2%. On the negative front, top decliners within the industry include Biogen Idec ( BIIB), down 1.9%, Novo Nordisk A/S ( NVO), down 0.9%, Regeneron Pharmaceuticals ( REGN), down 0.6%, Amgen ( AMGN), down 0.7% and Gilead ( GILD), down 0.6%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Shire ( SHPG) is one of the companies pushing the Drugs industry higher today. As of noon trading, Shire is up $1.78 (1.6%) to $114.62 on average volume. Thus far, 186,477 shares of Shire exchanged hands as compared to its average daily volume of 306,900 shares. The stock has ranged in price between $113.07-$114.66 after having opened the day at $113.07 as compared to the previous trading day's close of $112.84.

Shire plc, a specialty biopharmaceutical company, engages in the research and development, manufacture, sale, and distribution of pharmaceutical products. It operates in three segments: Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT), and Regenerative Medicine (RM). Shire has a market cap of $21.0 billion and is part of the health care sector. Shares are up 21.4% year to date as of the close of trading on Wednesday. Currently there are 9 analysts that rate Shire a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Shire as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Shire Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Novartis ( NVS) is up $0.47 (0.6%) to $75.08 on average volume. Thus far, 677,587 shares of Novartis exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $74.57-$75.08 after having opened the day at $74.78 as compared to the previous trading day's close of $74.61.

Novartis AG engages in the research, development, manufacture, and marketing of a range of healthcare products worldwide. Novartis has a market cap of $182.8 billion and is part of the health care sector. Shares are up 17.9% year to date as of the close of trading on Wednesday. Currently there are 6 analysts that rate Novartis a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Novartis as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures, notable return on equity and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Novartis Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Actavis ( ACT) is up $1.49 (1.1%) to $140.49 on average volume. Thus far, 624,246 shares of Actavis exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $138.76-$140.73 after having opened the day at $138.76 as compared to the previous trading day's close of $139.00.

Actavis, Inc., an integrated specialty pharmaceutical company, engages in developing, manufacturing, marketing, selling, and distributing generic, branded generic, brand, biosimilar, and over-the-counter pharmaceutical products worldwide. Actavis has a market cap of $18.2 billion and is part of the health care sector. Shares are up 61.6% year to date as of the close of trading on Wednesday. Currently there are 12 analysts that rate Actavis a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Actavis as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Actavis Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists